

Major Onpattro Market Trend 2025-2034: Broadening Patient Access Through Strategic Drug Approvals

*The Business Research Company's
Onpattro Global Market Report 2025 –
Market Size, Trends, And Global Forecast
2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, March 12, 2025

[/EINPresswire.com/](#) -- What Is the
Current and Future Market Size of
Onpattro?

The Onpattro market has witnessed substantial growth in recent years, demonstrating a strong historical compound annual growth rate (HCAGR).

- The market size is projected to expand from \$XX million in 2024.
- It is expected to reach \$XX million in 2025.
- The estimated compound annual growth rate (CAGR) for this period is XX%.



Updated 2025 Market
Reports Released: Trends,
Forecasts to 2034 – Early
Purchase Your Competitive
Edge Today!

”

*The Business Research
company*

Key drivers behind this growth include:

- Rising healthcare expenditures
- Increased investments in research and development
- Greater public awareness of rare diseases
- A growing elderly population
- A rising prevalence of hereditary transthyretin-mediated amyloidosis (hATTR)

Looking further ahead, from 2025 to 2029, the Onpattro market is expected to continue its upward trajectory with a forecast compound annual growth rate (FCAGR).

- The market is anticipated to reach \$XX million by 2029.
- The projected CAGR for this period is XX%.

Factors contributing to this expected growth include:

- Expanding collaborations and licensing agreements



The Business
Research Company

The Business Research Company

- Increasing rates of chronic diseases
- Growing biopharmaceutical partnerships
- A higher prevalence of transthyretin amyloidosis
- Strengthened regulatory support

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp>

What Are the Key Drivers of [Onpattro Market Growth](#)?

A significant factor driving the expansion of the Onpattro market is the increasing prevalence of hereditary transthyretin-mediated amyloidosis (hATTR). This rare genetic disorder occurs when mutated transthyretin (TTR) proteins form harmful deposits, leading to complications affecting the heart and nervous system.

Advancements in genetic testing, enhanced diagnostic capabilities, and improved awareness have contributed to a higher rate of hATTR diagnosis. Consequently, more patients are receiving treatment with Onpattro, a drug that silences the TTR gene to reduce amyloid protein production and prevent organ damage.

According to Verywell Health, a US-based health information platform, the global prevalence of hereditary transthyretin-mediated amyloidosis is estimated to range between 5,500 and 38,500 individuals. However, only a small percentage of cases are currently diagnosed, highlighting a significant opportunity for market growth.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report>

Who Are the Major Players in the Onpattro Market?

One of the leading players in the Onpattro market is Alnylam Pharmaceuticals Inc. This pharmaceutical company has played a pivotal role in shaping the market landscape and is expected to continue influencing its future direction.

What Emerging Trends Are Shaping the Onpattro Market?

A key trend driving market expansion is the strategic effort by pharmaceutical companies to extend the therapeutic applications of Onpattro. By submitting supplemental drug applications, these companies aim to increase the drug's market potential by targeting additional indications, patient demographics, and new formulations.

For example, Alnylam Pharmaceuticals has taken a significant step in this direction. In February 2023, the company's Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran) was accepted, with the goal of addressing cardiomyopathy associated with transthyretin amyloidosis (ATTR).

How Is the [Onpattro Market Segmented](#)?

The Onpattro market is divided into several key segments:

1. By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin

Amyloidosis, Other Transthyretin-Related Amyloidoses

2. By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3. By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

What Is the Regional Outlook for the Onpattro Market?

In 2024, North America held the largest share of the Onpattro market. However, Asia-Pacific is expected to emerge as the fastest-growing region during the forecast period. Additional regions covered in this market analysis include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Peruse Through More Similar Reports From [The Business Research Company](#):

Oncology Biosimilars Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report>

Rituximab Biosimilars Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report>

Biosimilar Hormones Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report>

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/792624556>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.